Substituted sulfonic acid n-[{aminoiminomethyl)phenylalkyl] -azaheterocyclamide compounds.

WHAT IS CLAIMED IS: 1. A compound of formula IEMI111.1 formula IEMI111.2 is phenyl or monocyclic heteroaryl;R is hydrogen, optionally substituted alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, R6O(CH2)X-, R6O2C(CH2)x-,Y1Y2NC(O)(CH2)x-, or or YlY2N(CH2)x-; R, is hydrogen, alkyl, hydroxy, alkoxy, Y'Y2N-, halogen, -CO2R6, -C(O)NY'Y2, -(CH2)IOR6, -(CH2)XNY'Y2, or -CN;STDC0830R2 and R3 are independently selected from hydrogen, hydroxy, alkoxy, Y'Y2N-, halogen, -CO2R6, C(O)NY1Y2,-(CH2)xOR6, -(CH2)XNY'Y2, -CN, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaralkyl, optionally substituted aralkenyl or optionally substituted heteroaralkenyl, or R2 and R3 taken together with the carbon atoms through which they are linked form an optionally substituted 5 to 7 membered fused cycloalkyl, optionally substituted 5 to 7 membered fused heterocyclyl ring or an optionally substituted 6 membered fused aryl, or an optionally substituted 5 to 7 membered fused heteroaryl ring;STDC0438R4 is hydrogen or optionally substituted lower alkyl, optionally substituted aralkyl or optionally substituted heteroaralkyl;X, and Xta are independently selected from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl, or X, and Xia taken together form oxo;STDC0758 X2 and X2a are hydrogen, or taken together form oxo;X3 is hydrogen, hydroxy, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl or optionally substituted heteroaralkyl, or X3 and one of X, and Xia taken together with the carbon atoms through which X3 and one of X, and X1a are linked form a 4 to 7 membered cycloalkyl or heterocyclyl ring; X4 is hydrogen, optionally substituted alkyl or an optionally substituted aralkyl;X5 and X5a are hydrogen or taken together are =NR5; R5 is hydrogen, R6O2C-, R6O-, cyano, R6CO-, optionally substituted lower alkyl, nitro or Y'Y2N-;STDC0791Y' and Y2 are independently hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaralkyl, or Y' and Y2 taken together with the N through which Y' and Y2 are linked form a 4 to 7 membered heterocyclyl;X6 and X6a are independently hydrogen, R7R8N- , R9O-, R7R8NCO-, R7R8NSO2-, R7R8NSO2N -, R7R8SO2O-, R9CO-, -CO2R,, -C(O)NY'Y2, -(CH2)XCO2R6, -(CH2)xC(O)NY1Y2,-(CH2)xOR6,-(CH2)xNY1Y2, halo, cyano or nitro;R6 is hydrogen, optionally substituted alkyl, optionally substituted aralkyl or optionally substituted heteroaralkyl;STDC0665R7 and R8 are independently hydrogen or optionally substituted lower alkyl, or one of R7 and R, is hydrogen and the other of R7 and R8 is R,0(O)CCH2- or lower acyl;R9 is hydrogen, optionally substituted lower alkyl, optionally substituted lower acyl or Rlo(O)CCH2-; R10 is hydrogen, optionally substituted lower alkyl, optionally substituted alkoxy or hydroxy;A is S or -CH=CH-; m is 0, 1, 2 or 3; n is 0, 1 2 or 3; and x is 1, 2, 3, 4 or 5, or a pharmaceutically acceptable salt thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

2. The compound of claim 1 wherein n=l and m=1.

3. The compound of claim 1 wherein X2 and X2 taken together are oxo.

4. The compound of claim 1 wherein X" X1a, X4 are hydrogen, and X3 is hydrogen or alkyl.

5. The compound of claim 1 wherein X5 and Xsa taken together are =NR5 wherein R5 is R602C-.

6. The compound of claim 1 wherein X5 and X5a taken together are =NR, wherein R5 is -OH.

7. The compound of claim 1 wherein X5 and X5a taken together are =NR5 wherein R5 is H.

8. The compound of claim 1 whereinEMI112.1 is phenyl and the carbon substituted with X5, X5a and R4HN- is attached meta relative to the attachment of the -(CH)nN- moiety to the phenyl.

9. The compound of claim 1 whereinEMI113.1 is thienyl and the carbon substituted with X5, X3a and R4HN- is attached in the 2 position relative to the sulfur of the thienyl and the attachment of the -(CH)nN- moiety is to the 4 position of the thienyl.

10. The compound of claim 1 wherein R is hydrogen, methyl, araikyl, heteroaralkyl, HO2CCH2-, H2NC(O)CH2-, or R6HNC(O)CH2-.

11. The compound of claim 1 wherein R, is hydrogen, alkyl, or halogen.

12. The compound of claim 1 wherein R2 and R3 are independently hydrogen, halogen, alkyloxy, amino, aryl, or heteroaryl.

13. The compound of claim 1 wherein R2 and R3 form an optionally substituted fused aryl or an optionally substituted fused heteroaryl ring wherein the substituent is halogen, alkyl, amino, hydroxy, or alkoxy.

14. The compound of claim 1 wherein R2 and R, form an optionally substituted fused cycloalkyl or an optionally substituted fused heterocyclyl in which the heteroatom is nitrogen wherein the substituent is hydrogen, Y'Y2N, or alkyl.

15. The compound of claim 1 wherein whereinEMI113.2 is phenyl and one of X6 and X6a is amino or hydroxy in a para position relative to theEMI113.3 moiety.

16. The compound of claim 1 wherein X6 and X6a are hydrogen.

17. The compound of claim 1 wherein A is -CH=CH-; and R2 and R3 taken together with the carbon atoms through which R2 and R3 are linked form an optionally substituted 5 or 6 membered heteroaryl ring or an optionally substituted 6 membered aryl ring.

18. The compound of claim 1 wherein A is -CH=CH-; R2 is hydrogen; and R3 is an optionally substituted heteroaryl ring or an optionally substituted 6 membered aryl ring.

19. The compound of claim 1 wherein A is S.

20. The compound of claim 1 wherein A is S; and R2 and R3 taken together with the carbon atoms through which R2 and R3 are linked form an optionally substituted 5 or 6 membered heteroaryl ring or an optionally substituted 6 membered aryl ring.

21. The compound of claim 1 wherein A is S; R2 is hydrogen; and R3 is an optionally substituted heteroaryl ring or an optionally substituted 6 membered aryl ring.

22. A compound according to claim 1 which is 3 - [3- (S)-(Benzothiophene-2-sulfonylamino) -2-oxo-pyrrolidin- 1 -ylmethyl] -benzamidine trifluoroacetate; 3- [3- (S)- [(Benzothiophene-2-sulfonyl)-methylamino]-2-oxo-pyrrolidin- 1 -ylmethyl]- benzamidine trifluoro acetate; 4- [3-(S)-(Benzo thiophene-2-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl]-thiophene-2- carboxamidine trifluoroacetate; 4- [3-(S)- [(Benzothiophene-2-sulfonyl] -methylamino] -2-oxo-pyrrolidin- 1 -ylmethyl] -thiophene2-carboxamidine trifluoroacetate; 3- [3-(S)-(4-Chlorobenzothiophene-2-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl]-benzamidine trifluoroacetate;STDC0683 3- [3- (S)-(6-Chlorobenzothiophene-2-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl ] -benzamidine trifluoroacetate; 3- [3 -(S)- [(4-Chlorobenzo [blthiophene-2-sulfonyl)-methylamino] -2-oxo-pyrrolidin- 1 -ylmethyll - benzamidine trifluoroacetate; 3 - [3-(S)- [(6-Chlorobenzo thiophene-2-sulfonyl)-methylamino] -2 -oxo-pyrrolidin- 1 -ylmethyl] benzamidine trifluoroacetate; 3- [3- (S)-(5-Chlorobenzo [b ]thiophene-2-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl]-benzamidine tri fluoro acetate;STDC0545 3- [3-(S)- [(5-Chlorobenzothiophene-2-sulfonyl)-methyl-amino]-2-oxo-pyrrolidin- 1 -ylmethyl] - benzamidine trifluoro acetate; 3- [3- (S)-(4-Methylbenzothiophene-2-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl] -benzamidine trifluoroacetate; 3- [3 -(S) -(6-Methylbenzothiophene-2-sulfonylamino)-2-oxo -pyrrolidin- 1 -ylmethyl] -benzamidine trifluoroacetate; 3-[3-(S)-(5-Methylbenzo[b]thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]-benzamidine trifluoroacetate;STDC0838 3-[3-(S)-(4,6-Dichlorobenzo[b]thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamidine trifluoro acetate; ([3- [3-(S)-(4,6-Dichlorobenzo thiophene-2-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl] phenyll -iminomethyl)-carbamic acid 2,2,2-trichloroethyl ester; 4-Amino-3 -[ 3-(S)-(4,6-dichlorobenzo[bithlophene-2-snifonylamino)-2-oxo-pyrrdidin- 1 ylmethyl]-benzamidine trifluoroacetate; 4-Hydroxy-3- [3 -(S)-(4,6-dichlorobenzo[b]thiophene-2-sulfonylamino)-2-oxo-pyrrolidin- 1 ylmethyl]-benzamidine trifluoroacetate; 3- [3-(S)-(6-Fluorobenzothiophene-2-sulfonylamino) -2-oxo-pyrrolidin- 1 -ylmethyl] -benzamidine trifluoroacetate;STDC0847 4- Amino-3 - [3- (S)- (6-fluorobenzothiophene-2-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl] benzamidine trifluoro acetate; 4-Hydroxy-3-[3-(S)-(6-fluorobenzo[b]thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamidine trifluoroacetate; 4-Amino-3-[3-(S)-(4-chlorobenzo[b]thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamidine trifluoroacetate; 4-Hydroxy-3-[3-(S)-(4-chlorobenzo[b]thiophene-2-sulfamylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamidine trifluoro acetate; 3-[3-(S)-(4-Chloro-thieno[3,2-c]pyridine-2-sulfonylamino)-2-oxo-pyrroldin-1-ylmethyl]benzamidine trifluoroacetate; 4-Hydroxy- 3- [3- (S)-(4-chloro-thieno [3,2-c]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin- 1 ylmethyl]-benzamidine trifluoroacetate;STDC0684 3-[3-(S)-(5-Chlorothieno[3,2-b]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamidine trifluoroacetate; 3-[3-(S)-(Thieno[3,2-b]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin- 1-ylmethyl]-benzamidine bistrifluoroacetate; 3-[3-(S)-(5-Chlorothieno[3,2-b]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]hydroxybenzamidine trifluoroacetate; 3- { 3-(S)-[(5-Chlorothieno[3,2-b]pyridine-2-sulfonyl)-methylamino] -2-oxo-pyrrolidin- 1 - ylmethyl } - benzamidine trifluoro acetate; 3-[3-(S)-(6-Chlorothieno[2,3-b]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamidine trifluoroacetate;STDC0855 3-[3-(S)-(Thieno[2,3-b]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]-benzamidine bistrifluoro acetate; 3-f 3-(S)-[(6-Chlorothieno[2,3-b]pyridine-2-sulfonyl)-methylamino]-2-oxo-pyrrolidin- 1 -ylmethyl } benzamidine trifluoroacetate; 4-Hydroxy-3-[2-oxo-3-(S)-(5-chlorothieno[3,2-b]pyridine-2-sulfonylamino)-pyrrolidin-1ylmethyl -benzamidine trifluoroacetate; 4-Hydroxy-3-[2-oxo-3-(S)-(thieno[3,2-b]pyridine-2-sulfonylamino)-pyrrolidin-1-ylmethyl]benzamidine bistri fluoroacetate; 4-Hydroxy-3-[2-oxo-3-(S)-(5-chlorothieno[3,2-b]pyridine-2-sulfonylamino)-pyrrolidin-1ylmethyl]-hydroxybenzamidine trifluoroacetate; 4-Amino-3-[2-oxo-3-(S)-(5-chlorothieno[3,2-b]pyridine-2-sulfonylamino)-pyrrolidin-1-ylmethyl]benzamidine trifluoroacetate;STDC0768 4-Amino-3-[2-oxo-3-(S)-(thieno[3,2-b]pyridine-2-sulfonylamino)-pyrrolidin-1-ylmethyl]benzamidine bi strifluoroacetate; 4-[3-(S)-(5-Chlorothieno[3,2-b]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]thiophene-2-carboxamidine trifluoroacetate; 4-[3-(S)-(5-Chlorothieno[3,2-b]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]thiophene-2-hydroxycarboxamidine trifluoroacetate; 4-f 3-(S)-[(5-Chlorothieno [3,2-b]pyridine-2-sulfonyl)-methylamino]-2-oxo-pyrrolidin- 1 - ylmethyl } thiophene-2-carboxamidine trifluoroacetate; 3-{3-(S)-[5-(2-Methylsulfanyl-pyrimidin-4-yl)-thiophene-2-sulfonylamino]-2-oxo-pyrrolidin-1ylmethyl)-benzamidine trifluoroacetate;STDC0842 3-f 3-(S)- [5-(2-Methoxy-pyrimidin-4-yl)-thiophene-2-sulfonylamino] -2-oxo-pyrrolidin- 1 ylmethyl)-benzamidine trifluoroacetate; 3-{3-(S)-[5-(2-Amino-pyrimidin-4-yl)-thiophene-2-sulfonylamino]-2-oxo-pyrrolidin-1-ylmethyl}benzamidine bi strifluoroacetate; 3-( 3-(S)-([5 -(2-Amino-pyrimidin-4-yl)-thiophene-2-sulfonyl] -methylamino)-2-oxo-pyrrolidin- 1 ylmethyl 1 -benzamidine bistrifluoroacetate; 3-[3-(S)-(5' -Chloro-[2,2' ]-bithiophenyl-5-sulfonylamino)-2-oxo-pyrrolidin- 1-ylmethyl]benzamidine trifluoroacetate; 4-Amino-3-[3-(S)-benzo[b]thiophene-2-sulfonylamino)-2-oxopyrrolidin-1-ylmethyl]benzamidine trifluoroacetate;STDC0865 4-Amino- 3 - [6-chlorobenzothiophene-2-sulfonylamino)-2-oxopyrrolidin- 1 ylmethyl]benzamidine trifluoroacetate; 4-Amino-3- [6-chlorobenzothiophene-2-sulfonylamino)-2-oxopyrrolidin- 1ylmethyl]hydroxybenzamidine trifluoroacetate; 3-[2-Oxo-3-(S)-(5-pyridin-3-yl-thiophene-2-sulfonylamino)-pyrrolidin-1-ylmethyl-benzamidine trifluoroacetate; 4-Amino-3-[2-oxo-3-(S)-(5-pyridin-3-yl-thiophene-2-sulfonylamino)-pyrrolidin-1-ylmethyl]benzamidine trifluoroacetate; 4-Hydroxy- 3- [2-oxo- 3-(S)-(5 -pyridin- 3 - yl-thiophene-2-sulfonylamino)-pyrrolidin- 1 -ylmethyli - benzamidine trifluoro acetate; 4-Hydroxy-3-[2-oxo-3-(S)-(5-pyridin-N-oxide-3-yl-thiophene-2-sulfonylamino)-pyrrolidin-1ylmethyl]-benzamidine trifluoroacetate;STDC0893 3- [2-Oxo- 3- (S) -(5 -pyridin-4-yl-thiophene-2-sulfonylamino) -pyrrolidin- 1 -ylmethyl]-benzamidine trifluoro acetate; 3- [3- (S) -(4-Chloro -thiophene-2- sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethylj -benzamidine trifluoroacetate; 3-{3-(S)-[5-(5-Chloropyridin-3-yl)-thiophene-2-sulfonylamino]-2-oxopyrrolidin-1ylmethyl J benzamidine trifluoroacetate; 3- [3-(S)-(4-Chloro-5-pyridin- 3-ylthiophene-2-sulfonylamino)-2-oxopyrrolidin- 1-ylmethyl]benzamidine trifluoroacetate; 4-Hydroxy-3-[3-(S)-(6-chlorobenzo[b]thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamide trifluoro acetate; 3-[3-(S)-(1 -Aminoisoquinoline-6-sulfonylamino)-2-oxopyrrolidin- l-ylmethyl]-benzamidine trifluoroacetate;STDC0662 4-Fluoro-3-[3-(S)-(5-pyridin-3-yl-thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamide trifluoroacetate; 2-Chloroquinoline-6-sulfonic acid {1-[3-(aminoiminomethyl)-benzyl]-2-oxo-pyrrolidin-3-(S)-yl}amide trifluoroacetate; 2-Aminoquinoline-6-sulfonic acid { 1 - [3-(aminoiminomethyl)-benzyl] -2-oxo-pyrrolidin- 3-(S)-yl } - amide bistrifluoroacetate; 4-Hydroxy-3-[3-(S)-(7-chloro-thieno[2,3-c]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin-1ylmethyl]-benzamidine trifluoroacetate; 4-Hydroxy-3-[3-(S)-(thieno[2,3-c]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamidine bistrifluoroacetate;STDC0672 4-Hydroxy-3-[3-(S)-(thieno[3,2-c]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl] benzamidine trifluoro acetate; 4-[3-(6-Fluorobenzo[b]thiophene-2-sulfonylamino)-2-oxo -pyrrolidin- 1 -ylmethyl] -thiophene-2 carboxamidine hydrochloride; 4-{3-(S)-[(3-Aminopropyl)-(6-fluorobenzo[b]thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1ylmethyl}-thiophene-2-carboxamidine bistrifluoroacetate; [[1 -(5-Carbamimidoyl-thiophen- 3-ylmethyl-2-oxo-pyrrolidin- 3-yl] - (6-fluorobenzo [b ]thiophen-2sulfonyl)-amino i-acetic acid trifluoroacetate;STDC0758 [Imino-(4- f 3- methoxynaphthalene-2-sulfonyl) -pyridin-2-ylmethyl- amino] -2-oxo-pyrrolidin- 1 ylmethyl )-thiophen-2-yl)-methyl]-carbamic acid ethyl ester; 4-Amino- 3 - { 3-(S)-[(7-methoxy-naphthalene-2- sulfonyl) -pyridine-2-ylmethyl-amino] -2-oxo pyrrolidin-l -ylmethyl) -benzamidine trifluoroacetate; 2- [[1 -(2-Amino-5-carbamimidoyl-benzyl)-2-oxo-pyrrolidin-3 -(S)-yl } -(7-methoxy-naphthalene-2sulfonyl)-amino]-acetamide trifluoroacetate; [Imino-(3-{3-[(7-methoxy-naphthalene-2-sulfonyl)-methylamino]-2-oxo-3-(S)-pyrrolidin-1ylmethyl}-4-amino-phenyl)-methyl]carbamic acid ethyl ester;STDC0688 4-Hydroxy-3- f 3-(S)- [ 5-(1 -Hydroxy-pyridin-4-yl)-thiophene-2-sulfonyl aminol -2-oxo-pyrrolidin- 1-ylmethyl}-benzamidine trifluoroacetate; 4-Amino-3-[3-(S)-(5-chloro-thieno[3 ,2-b]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl ] - hydroxybenzamidine. trifluoroacetate; 4-Amino-3-[3-(S)-(5-methoxy-thieno[3,2-b]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin-1ylmethyl]-benzamidine bistrifluoro acetate; 3-[3-(S)-(5-Isoxazol-3-yl-thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]-benzamidine trifluoroacetate;STDC0687 4-Amino-3-[3-(S)-(5-isoxazol-3-yl-thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamidine trifluoro acetate; 4-Hydroxy- 3- [3 -(S)- (5-isoxazol- 3-yl-thiophene-2-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl } benzamidine trifluoroacetate; 3-(S)- [3-( [2,2' ] -Bithiophenyl -5 -sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl]-benzamidine trifluoroacetate; 4-Amino-3-[3-(S)-([2,2']-bithiophenyl-5-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamidine trifluoroacetate; 4-Amino-3-[3-(S)-(5' -chloro- [2,2'] -bithiophenyl-5-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl] benzamidine trifluoroacetate;STDC0478 4-Hydroxy- 3- [3-(S)-(5 -chloro- [2,2'] -bithiophenyl-5-sulfonylamino)-2-oxo-pyrrolidin- 1 ylmethyl -benzamidine hydrochloride; 4-Hydroxy-3-[3-(S)-(5'-chloro-[2,2']-bithiophenyl-5-sulfonylamino)-2-oxo-pyrrolidin-1ylmethyl]-hydroxybenzamidine; or 4-[3-(S)-(6-Fluoro-benzo[b]thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]-pyridine-2carboxamidine hydrochloride.

23. A compound according to claim 22 which is 3- [3-(S)-[(llenzo[b]thiophene-2-sulfonyl)-methylamino] -2-oxo-pyrrolidin- 1 -ylmethyl]benzamidine trifluoro acetate.

24. A compound according to claim 22 which is 4- [3-(Benzo thiophene-2-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethylj -thiophene-2- carboxamidine trifluoroacetate.

25. A compound according to claim 22 which is 3-[3-(S)-(6-Chlorobenzo[b]thiophene-2-sulfonyl amino)-2-oxo-pyrrolidin- 1 -ylmethyl]-benzamidine trifluoroacetate.

26. A compound according to claim 22 which is 3-[3-(S)-[(6-Chlorobenzo[b]thiophene-2-sulfonyl)-methylamino]-2-oxo-pyrrolidin-1-ylmethyl]benzamidine trifluoro acetate.

27. A compound according to claim 22 which is 3-[3-(4,6-Dichlorobenzo[b]thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]-benzamidine trifluoroacetate.

28. A compound according to claim 22 which is ([3-[3-(S)-(4,6-Dichlorobenzo[b]thiophene-2-sulfonylamino)-2-oXo-pyrrolidin-1 -ylmethyl]phenyli -iminomethyl) -carbamic acid 2,2,2-trichloroethyl ester.

29. A compound according to claim 22 which is 3- [3-(6-Fluorobenzo[bithiophene-2-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl] -benzamidine trifluoroacetate.

30. A compound according to claim 22 which is 4-Amino-3- [2-oxo-3-(S)-( 6-fluorobenzo[bjthiophene-2-sulfamylamino)-pyrrolidin- 1 -ylmethylj- benzamidine trifluoroacetate.

31. A compound according to claim 22 which is 4-Hydroxy-3-[2-oxo-3-(S)-( 6-fluorobenzo[b]thiophene-2-sulfamylamino)-pyrrolidin-1-ylmethyl]benzamidine trifluoroacetate.

32. A compound according to claim 22 which is 4-Hydroxy- 3-[2-oxo-3-(S)-(4-chloro-thieno[ 3,2-c]pyridine-2-sulfamylamino)-pyrrolidin- 1 ylmethyl]-benzamidine trifluoroacetate.

33. A compound according to claim 22 which is 3-[3-(S)-(Thieno[3,2-b]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]-benzamidine bistrifluoroacetate.

34. A compound according to claim 22 which is 3-[3-(S)-(Thieno[2,3-b]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]-benzamidine bistrifluoro acetate.

35. A compound according to claim 22 which is 4-Amino-3- [2-oxo-3-(S)-(thieno[3 ,2-bjpyridine-2-sulfonylamino)-pyrrolidin- 1 -ylmethyl] benzamidine bi strifluoro acetate.

36. A compound according to claim 22 which is 3-f 3-(S)- [S-(2-Methylsu1fanylyrimidin-4-yl)-thiophene-2-sulfonylamino]-2-oxo-pyrrdidin- 1 - ylmethyl) -benzamidine trifluoroacetate.

37. A compound according to claim 22 which is 4-Amino-3- [6-Chlorobenzo[bjthiophene-2-sulfonylamino)-2-oxopyrrolidin- 1 ylmethyl]benzamidine trifluoroacetate.

38. A compound according to claim 22 which is 4-Amino-3- [6-Chlorobenzo[b]thiophene-2-sulfonylamino)-2-oxopyrrolidin- 1 ylmethyl]hydroxybenzamidine trifluoroacetate.

39. A compound according to claim 22 which is 3- [2-Oxo-3-(S)-(5-pyridin-3-yl-thiophene-2-sulfonylamino)-pyrrolidin- 1 -ylmethylj -beuzamidine trifluoroacetate.

40. A compound according to claim 22 which is 4-Hydroxy-3-[2-oxo-3-(S)-(5-pyridin-3-yl-thiophene-2-sulfonylamino)-pyrrolidin- 1 -ylmethyl]benzamidine trifluoroacetate.

41. A compound according to claim 22 which is 4-Hydroxy-3-[2-oxo-3-(S)-(5-pyridin-N-oxide-3-yl-thiophene-2-sulfonylamino)-pyrrolidin-1ylmethyl]-benzamidine trifluoroacetate.

42. A compound according to claim 22 which is 4-Hydroxy-3-[ 3-(S)-(6-chloro-benzothiophene-2-sulfonylamino)-2-oxo-pyrrolidin- 1 -yl] benzamide trifluoroacetate.

43. A compound according to claim 22 which is 4-Hydroxy- 3- [3-(S)-(7-chloro-thieno[2,3-c]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin- 1 ylmethyl]-benzamidine trifluoroacetate.

44. A compound according to claim 22 which is 4-Hydroxy-3-[3-(S)-(thieno[2,3-c]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamidine bistrifluoroacetate.

45. A compound according to claim 22 which is 4-Hydroxy-3-[3-(S)-(thieno[3,2-c]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamidine trifluoro acetate.

46. A compound according to claim 22 which i 4-Hydroxy- 3- { 3-(S)- [ 5 -(1 -Hydroxy-pyridin-4- yl)-thiophene-2-sulfonyl amino] -2-oxo-pyrrolidin1 - ylmethyl) -beuzamidine trifluoroacetate.

47. A compound according to claim 22 which is 4-Amino-3 -[3-(S)-(S-methoxy-thieno[3 ,2-b]pyridine-2-sulfonylamino)-2-oxo-pyrrolidin- 1 - ylmethyl]-benzamidine bistrifluoroacetate.

48. A compound according to claim 22 which is 4-Amino-3-[3-(S)-(5-isoxazol-3-yl-thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamidine trifluoro acetate.

49. A compound according to claim 22 which is 4-Hydroxy-3-[3-(S)-(5-isoxazol-3-yl-thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl}benzamidine trifluoroacetate.

50. A compound according to claim 22 which is 4-Amino-3-[3-(S)-([2,2']-bithiophenyl-5-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]benzamidine trifluoroacetate.

51. A compound according to claim 22 which is 4-Amino- 3- [3-(S)-(5 ' -chloro- [2,2 ' ] -bithiophenyl-5-sulfonylamino)-2-oxo-pyrrolidin- 1 -ylmethyl] benzamidine trifluoroacetate.

52. A compound according to claim 22 which is 4-Hydroxy-3- [ 3-(S)-(5 ' -chloro-[2,2']-bithiophenyl-5-sulfonylamino)-2-oxo-pyrrolidin- 1ylmethyl )-benzamidine hydrochloride.

53. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 and a pharmaceutically acceptable carrier.

54. A method for treating a patient suffering from a physiological disorder capable of being modulated by inhibiting an activity of Factor Xa comprising administering to the patient a therapeutically effective amount of the compound according to claim 1.

55. The method according to claim 54 wherein the physiological disorder is venous vasculature, arterial vasculature, abnormal thrombus formation, acute myocardial infarction, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy, percutaneous transluminal coronary angioplasty, transient ischemic attacks, stroke, intermittent claudication or bypass grafting of the coronary or peripheral arteries, vessel luminal narrowing, restenosis post coronary or venous angioplasty, maintenance of vascular access patency in long-term hemodialysis patients, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery, a risk of pulmonary thromboembolism, or disseminated systemic intravascular coagulopathy occurring in vascular systems during septic shock, certain viral infections or cancer.

56. The method according to claim 54 wherein the physiological disorder abnormal thrombus formation, acute myocardial infarction, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy, transient ischemic attacks, intermittent claudication or bypass grafting of the coronary or peripheral arteries, restenosis post coronary or venous angioplasty, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery or a risk of pulmonary thromboembolism.

57. The method according to claim 54 wherein the physiological disorder stroke, vessel luminal narrowing, maintenance of vascular access patency in long-term hemodialysis patients, or disseminated systemic intravascular coagulopathy occurring in vascular systems during septic shock, certain viral infections or cancer.